Stellungnahme der DGS zu Olaparib (Lynparza®)

• Literatur

• 1 Weide R, Feiten S, Friesenhahn V. et al. Metastatic breast cancer: prolongation of survival in routine care is restricted to hormone-receptor- and Her2-positive tumors. Springerplus 2014; 3: 535
• 2 Gennari A, Conte P, Rosso R. et al. Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies. Cancer 2005; 104 (08) 1742-1750
• 3 Joy AA, Ghosh M, Fernandes R. et al. Systemic treatment approaches in her2-negative advanced breast cancer-guidance on the guidelines. Curr Oncol 2015; 22 (Suppl. 01) S29-S42
• 4 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): S3-Leitlinie Früherkennung, Diagnose, Therapie und Nachsorge des Mammakarzinoms, Version 4.1, 2018 AWMF. http://www.leitlinienprogramm-onkologie.de/leitlinien/mammakarzinom/
• 5 Cardoso F, Costa A, Senkus E. et al. 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). Ann Oncol 2017; 28 (12) 3111
• 6 Fasching P, Hu C, Hart SN. et al. Cancer predisposition genes in metastatic breast cancer – Association with metastatic pattern, prognosis, patient and tumor characteristics. San Antonio Breast Cancer Symposium; 2019
• 7 Sung P, Klein H. Mechanism of homologous recombination: mediators and helicases take on regulatory functions. Nature Reviews Molecular Cell Biology 2006; 7 (10) 739-750
• 8 O’Connor MJ. Targeting the DNA damage response in cancer. Molecular cell 2015; 60 (04) 547-560
• 9 Clovis Oncology, Fachinformation Rubraca (Stand 02/2019).
• 10 Tesaro, Fachinformation Zejula (Stand 06/2019).
• 11 AstraZeneka, Fachinformation Lynparza (Stand 10/2019).
• 12 Pfizer, Fachinformation Talzenna (Stand 06/2019).
• 13 Robson M, Im SA, Senkus E. et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med 2017; 377 (06) 523-533
• 14 Arbeitsgemeinschaft Gynäkologische Onkologie e. V. Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer – Version 1. 2019.
• 15 Muller V, Nabieva N, Haberle L. et al. Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registry. Breast 2018; 37: 154-160
• 16 Schnipper LE, Davidson NE, Wollins DS. et al. Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received. J Clin Oncol 2016; 34 (24) 2925-2934
• 17 Cherny NI, Sullivan R, Dafni U. et al. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies. the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) 2015; 26 (08) 1547-1573